The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2015
At a glance
- Drugs Afatinib (Primary)
- Indications Glioma; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- 09 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 09 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015, according to ClinicalTrials.gov record.